CHMP backs J&J's teclistamab for earlier-line relapsed/refractory myeloma

CHMP moves teclistamab toward second line

On 18 September 2026, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending TECVAYLI (teclistamab) for relapsed/refractory multiple myeloma in patients who have had at least one prior therapy — an earlier-line indication that expands on teclistamab's current later-line EU label ^[1]. The signal was reported by J&J's own release and corroborated the same day by OncLive, whose account specifies teclistamab monotherapy in the earlier-line setting ^[1][2].

Teclistamab is a BCMA×CD3 bispecific T-cell engager, marketed by Janssen Biotech under BLA761291 ^[7]. Teclistamab is already established in Europe: the European Commission granted full approval of TECVAYLI plus daratumumab for relapsed/refractory myeloma on 21 August 2026 ^[6], and the US FDA cleared TECVAYLI plus DARZALEX FASPRO as early as second line on 5 March 2026 ^[5]. The current US label still frames teclistamab as combination therapy with daratumumab/hyaluronidase for patients with at least one prior line that included a proteasome inhibitor and an immunomodulatory agent, or as monotherapy only after four prior lines ^[4]. A CHMP recommendation after one prior therapy therefore continues teclistamab's steady march from a last-resort option toward the earlier lines where patient volumes and competitive stakes are far larger.

Why it matters

Earlier-line access is where a BCMA bispecific franchise is won or lost. Each line the label moves up multiplies the eligible population and the number of prescribing decisions where teclistamab sits on the menu before a competitor is even considered. A CHMP positive opinion is a recommendation, not a marketing authorisation: the European Commission typically issues its binding decision within roughly two months of the opinion, which places a likely EU authorisation in the November 2026 window — Prognyx's estimate from the standard post-opinion clock, not a date J&J has published.

J&J is not defending a single asset. Its Q2 2026 results flagged TALVEY (talquetamab, a GPRC5D bispecific) plus DARZALEX FASPRO in earlier-line myeloma as a pipeline highlight and listed TECVAYLI among the oncology drivers of Innovative Medicine growth ^[10]. The company is running a Phase 3 trial of talquetamab-plus-teclistamab combinations against standard EPd/PVd regimens (NCT06208150, n=838, active but no longer recruiting, primary completion listed 1 April 2026, no results yet posted) ^[12], and — tellingly — is testing whether its own investigational agent JNJ-79635322 can beat teclistamab head-to-head in a 700-patient Phase 3 (NCT07518186, recruiting) ^[11]. J&J is engineering teclistamab's eventual successor while pushing teclistamab into earlier lines.

What to watch next

• The European Commission's binding decision on this indication, expected within roughly two months of the opinion (Prognyx estimate: around November 2026).
• Readout of the talquetamab-plus-teclistamab Phase 3 (NCT06208150), whose primary completion is listed as 1 April 2026 with no results yet posted ^[12].
• The JNJ-79635322-versus-teclistamab head-to-head (NCT07518186), which will define whether J&J cannibalises its own franchise ^[11].

Investigator and NCI trials continue to widen teclistamab's footprint — daratumumab combinations (NCT06948084, recruiting) ^[13], iberdomide combinations (NCT06465316, recruiting) ^[14], and new tumor types including plasmablastic lymphoma (NCT07332507) ^[15] and Waldenström's macroglobulinemia (NCT07791498, not yet open) ^[16]. Nature Medicine has published a randomized Phase 2 of teclistamab versus lenalidomide-dexamethasone in high-risk smoldering myeloma ^[17], signalling ambitions well upstream of the relapsed setting.

The now-what

For a competing BCMA program, three options are on the table. First, contest the second-line data directly — the earlier-line battle will be decided on depth and durability of response, not on being present in the class. Second, differentiate on administration or safety, since teclistamab carries a known post-marketing adverse-event profile now under real-world FAERS scrutiny ^[18]. Third, target the settings J&J has not yet locked — the smoldering and non-myeloma indications where the label has not moved.

What Prognyx could not verify

The ANGLE frames this against Pfizer's elranatamab and AbbVie's etentamig, but the dossier carries no primary regulatory record for either. Prognyx found no CHMP or FDA status for elranatamab beyond one M.D. Anderson trial (NCT07382739, recruiting) ^[19] and academic literature, and nothing at all on etentamig — so this briefing does not characterise their competitive standing. The CHMP opinion here is sourced from J&J's release and same-day OncLive coverage, not the EMA's own meeting-highlights page; OncLive characterises the recommendation as teclistamab monotherapy, while a separately dated CancerNetwork headline frames it as a combination and, dated June 2026, could not be reconciled here against the 18 September event and may reflect an earlier, distinct opinion.

Verdict: Moderate, near-term threat to any BCMA bispecific competing for second-line EU share — window to act closes with the EC decision expected around November 2026.